Compare CRSP & PFSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRSP | PFSI |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.8B |
| IPO Year | 2016 | 2018 |
| Metric | CRSP | PFSI |
|---|---|---|
| Price | $56.82 | $92.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 8 |
| Target Price | $70.29 | ★ $131.63 |
| AVG Volume (30 Days) | ★ 1.4M | 497.3K |
| Earning Date | 05-05-2026 | 04-21-2026 |
| Dividend Yield | N/A | ★ 1.29% |
| EPS Growth | N/A | ★ 59.25 |
| EPS | N/A | ★ 9.30 |
| Revenue | $289,590,000.00 | ★ $984,629,000.00 |
| Revenue This Year | $743.50 | N/A |
| Revenue Next Year | $163.21 | $16.02 |
| P/E Ratio | ★ N/A | $9.98 |
| Revenue Growth | ★ 9169.85 | 3.05 |
| 52 Week Low | $33.03 | $82.65 |
| 52 Week High | $78.48 | $160.36 |
| Indicator | CRSP | PFSI |
|---|---|---|
| Relative Strength Index (RSI) | 65.66 | 56.30 |
| Support Level | $51.64 | $91.78 |
| Resistance Level | $60.63 | $105.00 |
| Average True Range (ATR) | 2.28 | 2.49 |
| MACD | 1.17 | 1.30 |
| Stochastic Oscillator | 94.14 | 92.11 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
PennyMac Financial Services Inc is a specialty financial services firm with a comprehensive mortgage platform mainly focused on the production and servicing of U.S. residential mortgage loans. The firm is also engaged in managing investments related to the U.S. mortgage market and provides products and services that leverage technologies to support customers. The company operates through two reportable operating segments: production and servicing. The production segment performs loan origination, acquisition, and sale activities, while the servicing segment performs servicing and subservicing of loans, early buyout transactions, and servicing of loans sourced and managed for PMT. The majority of revenue comes from the production segment.